Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review

Author:

AlSharoqi Isa Ahmed,Aljumah Mohamed,Bohlega Saeed,Boz Cavit,Daif Abdelkader,El-Koussa Salam,Inshasi Jihad,Kurtuncu Murat,Müller Thomas,Retief Chris,Sahraian Mohammad Ali,Shaygannejad Vahid,Slassi Ilham,Taha Karim,Zakaria Magd,Sørensen Per Soelberg

Funder

Merck Serono Middle East FZ-LLC

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Reference74 articles.

1. Shimizu Y, Ikeguchi R, Kitagawa K. When and how disease-modifying drugs for multiple sclerosis should be changed in daily practice. Clin Exp Immunol. 2017;8:71–80.

2. Zakaria M. Smoke and mirrors: Limited value of relative risk reductions for assessing the benefits of disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2015;4:187–91.

3. Comi G, Radaelli M, Soelberg SP. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389:1347–56.

4. Burks JS. A practical approach to immunomodulatory therapy for multiple sclerosis. Phys Med Rehabil Clin N Am. 2005;16:449–66.

5. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2018. Available at https://www.whocc.no/atc_ddd_index. Accessed April 2020.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3